These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24620781)

  • 1. Are calcium-based phosphate binders ever preferable in dialysis patients?
    Jain N; Reilly RF
    Semin Dial; 2014; 27(3):269-72. PubMed ID: 24620781
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphate Binders and Targets Over Decades: Do We have it Right Now?
    Marcuccilli M; Chonchol M; Jovanovich A
    Semin Dial; 2017 Mar; 30(2):134-141. PubMed ID: 28064444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer.
    Wrong O; Harland C
    Nephrol Dial Transplant; 2008 Jun; 23(6):2108; author reply 2101-2. PubMed ID: 18400812
    [No Abstract]   [Full Text] [Related]  

  • 4. How KDIGO will (or will not) influence the management of hyperphosphatemia.
    Kovesdy CP
    Semin Dial; 2011; 24(1):35-6. PubMed ID: 21338391
    [No Abstract]   [Full Text] [Related]  

  • 5. When is Vitamin D contraindicated in dialysis patients?
    Lewin E; Olgaard K
    Semin Dial; 2009; 22(3):240-2. PubMed ID: 19572998
    [No Abstract]   [Full Text] [Related]  

  • 6. When is Vitamin D contraindicated in dialysis patients?
    Brown HJ; Cunningham J
    Semin Dial; 2009; 22(3):237-40. PubMed ID: 19572997
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
    Sherman RA
    Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
    Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
    J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using concordance with dosing techniques to achieve phosphate control.
    Koester LA; Rothstein M
    Nephrol News Issues; 2013 Nov; 27(12):22, 24, 26-8 passim. PubMed ID: 24354233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperphosphatemia in renal failure.
    Robb M
    RN; 2008 Dec; 71(12):26-30; quiz 31. PubMed ID: 19108567
    [No Abstract]   [Full Text] [Related]  

  • 14. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label use of phosphate binders in non-dialysis-dependent CKD.
    Winkelmayer WC; Chertow GM
    Am J Kidney Dis; 2010 Nov; 56(5):813-6. PubMed ID: 20970022
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
    Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
    J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach.
    Novak JE; Szczech LA
    Semin Dial; 2009; 22(1):56-63. PubMed ID: 19000107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis.
    Hamano T; Fukagawa M
    Kidney Int; 2024 Aug; 106(2):191-195. PubMed ID: 39032965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.